Abstract
Objectives: Aflibercept targets vascular endothelial growth factor and placental growth factor. We evaluated activity and toxicity of aflibercept in recurrent/persistent endometrial cancer patients. Biomarkers and association with clinical characteristics and outcome were explored. Methods: Eligible patients had measurable disease; 1-2 prior cytotoxic regimens; performance status 0-2. Aflibercept 4 mg/kg IV q14 days (28-day cycles) was administered until disease progression or prohibitive toxicity. Primary endpoints were the proportion of patients with progression-free survival at 6 months (PFS6) and tumor response rate. A flexible two-stage group sequential design to detect 20% increases in the proportion of patients responding or enduring PFS6 with 90% power (α = 10%) was employed. Results: Forty-nine patients were enrolled; five were excluded: wrong primary (2), second primary (1), wrong cell type (1); and never treated (1). Median age was 64 (range 48-83). Eighteen patients (41%) had two prior regimens; 27 (61%) had prior radiation. The PFS6 rate was 41%; three patients (7%, 90% CI: 2-17) had partial response. Of note, 10 patients (23%) met the PFS6 endpoint without starting a subsequent therapy; the remaining eight patients discontinued therapy for toxicity and started another therapy before 6 months elapsed. Median PFS and overall survival were 2.9 months and 14.6 months, respectively. Significant grade 3/4 toxicities were: cardiovascular (23%/5%), constitutional (7%/0), hemorrhage (2%/5%), metabolic (7%/2%), and pain (18%/0). Two treatment-related deaths were recorded: GI perforation (1), and arterial rupture (1). FGF1 expression was associated with response. Conclusions: Aflibercept met pretrial activity parameters, but was associated with significant toxicity at this dose and schedule in this population.
Original language | English (US) |
---|---|
Pages (from-to) | 538-543 |
Number of pages | 6 |
Journal | Gynecologic oncology |
Volume | 127 |
Issue number | 3 |
DOIs | |
State | Published - Dec 2012 |
Keywords
- Aflibercept
- Endometrial cancer
- Fibroblast growth factor
- Toxicity
- VEGF Trap
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology
MD Anderson CCSG core facilities
- Clinical Trials Office